Overview

Safety and Efficacy of YHD1023 in Erectile Dysfunction

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety and efficacy of oral YHD1023 5g or 10g on erectile dysfunction to investigate the optimal recommended dosage. Study period is 12 weeks including 4weeks of follow-up period without treatment. Study patients will fill in the international index of erectile function questionnaire and life satisfaction questionnaires.
Phase:
Phase 2
Details
Lead Sponsor:
Yuhan Corporation
Treatments:
Tadalafil